Q-omics provides the consensus-scored ZNF512B profile across patient tissues and cancer cell-line models. ZNF512B expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, ZNF512B is differentially expressed in 9, with the highest sampling consensus in LIHC. Additionally, ZNF512B RNA expression shows 20,461 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight CESC, LIHC, and ACC as cancer lineages where ZNF512B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZNF512B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZNF512B survival associations across molecular data types. ZNF512B RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZNF512B RNA expression–survival associations across cancer types. High ZNF512B expression shows unfavorable associations in CESC, ACC, BLCA, SKCM and LIHC, but favorable associations in ESCA. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify CESC as the clearest survival context for ZNF512B RNA expression.
This table summarizes ZNF512B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for ZNF512B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZNF512B shows lower tumor expression in THCA and higher tumor expression in LIHC, KIRC, LUAD, LUSC and CHOL. The LIHC box plot shows higher ZNF512B RNA expression in tumor versus normal tissue (log2 FC = +1.541, t-test p < 0.001).
This table shows molecular features associated with ZNF512B in patient tissues and cancer cell lines. In patient samples, ZNF512B shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, ZNF512B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUSC and UPPER_AERODIGESTIVE_TRACT.
